On August 9, 2023 HLB Life Science R&D, a subsidiary of HLB Life Science, is introducing next-generation targeted anticancer substances from the Lead Discovery Center (LDC), a global new drug candidate research institute in Germany, and conducting joint research (Press release, HLB Life Science, AUG 9, 2023, View Source;word=&page=1&v=386 [SID1234649276]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HLB Life Science R&D announced on the 9th that it signed a contract to acquire the global rights to the new anticancer substance discovered by LDC. The acquisition amount consists of a portion of the upfront payment, as well as stage-by-stage milestones and sales royalties.

LDC is a company that was spun off in 2008 from the Max Planck Society, a world-class research institute in Germany that has produced 32 Nobel Prize winners. Since its establishment, it has transferred more than 20 new drug technologies to leading global pharmaceutical companies. It is currently conducting more than 120 research projects on various diseases, including cancer, autoimmune, metabolic, cardiovascular, central nervous, and infection.

The targeted anticancer substance introduced by HLB Life Science R&D this time was also created through collaboration with the Max Planck Society Institute of Molecular Physiology. The substance, which inhibits the transcription process of a specific gene that helps cancer cells damaged by anticancer drugs to recover on their own, has confirmed a high killing effect on cancer cells through early research in the non-clinical stage.

HLB Life Science R&D plans to complete the non-clinical stage through joint research with LDC along with the new drug substance technology transfer and enter the clinical stage as quickly as possible.

Han Yong-hae, Chief Technology Officer (CTO) of HLB Group and Head of HLB Life Science R&D, said, "After a long period of in-depth discussions with LDC on discovering targeted anticancer drugs with new mechanisms, we recently agreed to begin full-scale development of next-generation targeted anticancer agents through joint research between the two companies."

He added, "As soon as we acquire LDC’s new drug substance, we will begin full-scale research and development at HLB Life Science R&D’s new drug research center."

"We are very pleased to form a strong partnership with HLB Life Science R&D," said Bert Klebble, CEO of LDC. "HLB Life Science R&D has the high capacity to stably develop anticancer compounds that are the culmination of our research results." Meanwhile, HLB Life Science R&D

is conducting research to develop an animal anticancer agent for the targeted anticancer agent ‘rivoceranib’ and to develop a medical cannabis treatment.